Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181793 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL19103607 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL14477972 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950236 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21448801 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950131 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950441 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950237 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL827134 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL11162297 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101023056-A | Levodopa prodrugs, and compositions and uses thereof | XENOPORT INC (US) | 2007-08-22 | — | — | CN | claimed |
| EP-0708947-B1 | CHEMICAL SOLUTION TO DETECT THE COUNTERFEIT OF PAPER CURRENCY | PIFFERI PIER GIORGIO (IT) | 1997-10-29 | — | — | EP | claimed |
| EP-0340262-B1 | SEMI-PERMEABLE MEMBRANES WITH AN INTERNAL DISCRIMINATING REGION | DOW CHEMICAL CO (US) | 1994-06-29 | — | — | EP | claimed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-11802144-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230331670-A1 | GLYCEROL COMPOUNDS AND METHODS OF USE | ENZYCHEM LIFESCIENCES CORP (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20150159163-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-8993738-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8759104-B2 | Cationic lipids | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130065308-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2013-03-14 | — | — | US | disclosed |
| CN-101023056-B | Levodopa prodrugs, and compositions and uses thereof | XENOPORT INC | 2011-05-25 | — | — | CN | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| CN-101023056-A | Levodopa prodrugs, and compositions and uses thereof | XENOPORT INC (US) | 2007-08-22 | — | — | CN | disclosed |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AEGERA THERAPEUTICS, INC. (CA) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | CES2 969/4885MEN1 4172/4885FAAH 4133/4885 |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | SCN1B, SCN3A, SCN1A | CES2 1450/4885MEN1 3389/4885FAAH 534/4885 |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AADAC, NAT1, PMP22 | CES2 301/4885MEN1 1818/4885FAAH 30/4885 |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SOD1, SOD3, SMN1; SMN2 | CES2 966/4885MEN1 4207/4885FAAH 4124/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CES2 2953/4885MEN1 4753/4885FAAH 2901/4885 |
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | CES2 4369/4885MEN1 3838/4885FAAH 4778/4885 |
| US-20130065308-A1 | CATIONIC LIPIDS | PLIN5, LPCAT3, IPO5 | CES2 2276/4885MEN1 1383/4885FAAH 1248/4885 |
| US-20230331670-A1 | GLYCEROL COMPOUNDS AND METHODS OF USE | GK, MGLL, DGAT2 | CES2 331/4885MEN1 3737/4885FAAH 174/4885 |
| US-11802144-B2 | Circular RNA compositions and methods | RBM17, RTCB, RBM22 | CES2 3332/4885MEN1 3881/4885FAAH 4319/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CES2 3346/4885MEN1 4828/4885FAAH 4742/4885 |
| US-20150159163-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | CES2 4369/4885MEN1 3838/4885FAAH 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.